Global Market for Breast Cancer Drugs to Grow at a CAGR of 9.3% in the 2016~2013 Period as New Drugs Enter the Market, Says TrendForce

The global market for breast cancer drugs is growing steadily due to rising patient population, introduction of new drugs and sales growth of Perjeta and Kadcyla. The latest biotechnology market report from TrendForce states that the global market scale of breast cancer drugs reached US$11.97 billion in 2016 and is forecast to expand at a CAGR of 9.3% to US$22.35 billion in 2023.

Based on the surface antigens of tumor cells, breast cancers are classified into three subtypes – HER2-positive, HR-positive and triple-negative. The market for drugs treating HER2-positive breast cancers has been growing rapidly, driven by the growing sales of Kadcyla and Perjeta worldwide. The global market scale of HER2-positive drugs was around US$7.41 billion in 2016, and TrendForce projects that it will arrive at U$12.42 billion in 2023 with the CAGR during the 2016~2023 period at about 7.7%.

Likewise, the market for HR-positive and triple-negative breast cancer drugs will keep booming over the next several years as sales of Ibrance are expected to remain robust and new drugs such as CDK4/6 inhibitors enter the market. According to TrendForce’s analysis, the global market scale of HR-positive and triple-negative breast cancer drugs came to US$4.56 billion in 2016 and is going to expand at a CAGR of 11.8% to reach US$9.93 billion in 2023.

Sean Liu, TrendForce’s associate research manager for biotechnology industry, pointed out that many pharmaceutical companies are attracted by the opportunities in the breast cancer market, which has an enormous patient population. “A large share of the numerous clinical solutions are for treating HER2-positive and the HR-positive subtypes,” said Liu. “Recently, pharmaceutical companies have recognized that there is unmet medical need for effective treatments related to triple-negative and BRCA subtypes of breast cancer. PI3K and PARP inhibitors, along with various new drugs, have been developed to address this demand. These drugs are now entering phase III clinical trials and are expected to arrive on the market within these three years.”